XML 33 R21.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)
3 Months Ended
Mar. 31, 2025
Summary of Significant Accounting Policies and Recent Accounting Pronouncements  
Schedule of Restricted Cash

March 31, 

December 31, 

2025

2024

Cash and cash equivalents

    

$

66,523

    

$

103,659

Restricted cash

 

2,087

 

2,009

Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows

$

68,610

$

105,668

Schedule of Financial Assets and Liabilities Measured at Fair Value

Fair Value Measurement Using:

    

    

Significant

    

Significant Other

    

Significant

March 31, 

Observable Inputs

Observable Inputs

Unobservable

Description

2025

(Level 1)

(Level 2)

(Level 3)

Cash equivalents

$

57,020

$

57,020

$

$

Restricted cash

$

2,087

$

2,087

$

$

Fair Value Measurement Using:

    

    

Significant

    

Significant Other

    

Significant

December 31, 

Observable Inputs

Observable Inputs

Unobservable

Description

2024

(Level 1)

(Level 2)

(Level 3)

Cash equivalents

$

80,930

$

80,930

$

$

Restricted cash

$

2,009

$

2,009

$

$

Schedule of Change in Asset Retirement Obligations

For the Three-Month Periods Ended March 31, 

2025

2024

Balance at beginning of period

    

$

2,821

    

$

2,401

Change in estimate

(1,576)

Amortization of interest

 

63

 

48

Effects of exchange rate changes

 

36

 

(9)

Balance at end of period

$

1,344

$

2,440

Schedule of Securities Excluded from Computation of Diluted Net Loss per Share

    

March 31, 

    

March 31, 

    

2025

    

2024

Share options

 

8,022,989

 

8,484,644

Restricted share units

3,389,750

4,094,750

Deferred share units

185,000

Warrants

700,000

700,000

 

12,112,739

 

13,464,394

Schedule of net loss for the segment

For the Three-Month Periods Ended March 31, 

2025

2024

Service revenue - related party

    

$

1,926

    

$

697

Operating expenses:

Cost of service revenue - related party

1,378

General and administrative

 

6,348

 

8,864

Clinical programs:

Botaretigene sparoparvovec

3,957

AAV-hAQP1

4,852

1,663

AAV-CNGB3 / AAV-CNGA3

(1,179)

AAV-GAD

1,459

2,170

Other ocular diseases

1,445

293

Manufacturing

17,359

18,360

Preclinical programs:

Gene regulation

2,286

2,499

Neurodegenerative diseases

426

391

Preclinical ocular diseases

625

327

Other research and development1

(624)

541

Johnson & Johnson Innovative Medicine reimbursement

(652)

Share-based compensation

4,887

6,960

Depreciation and amortization

3,081

3,275

Total operating expenses

43,522

47,469

Other segment items2

1,615

26,330

Segment net loss

$

(39,981)

(20,442)

Adjustments or reconciling items

Net loss

$

(39,981)

$

(20,442)

1 Other research and development is comprised of all other costs including payroll and payroll related costs, travel, rent and facilities costs and other non-program specific expenses.

2 Other segment items is comprised of foreign currency gain (loss), interest income, interest expense and gain on sale of nonfinancial assets.

Schedule of Long-lived Assets by Geographical Area

    

March 31, 

    

December 31, 

2025

2024

United States

$

2,515

$

7,209

United Kingdom

 

28,255

 

28,419

European Union

103,487

100,845

$

134,257

$

136,473